Lifesaver: Company co-founded by Israeli begins selling coronavirus-killing nasal spray in Israel
Enovid releases a small dose of nitric oxide, which is 99.9% effective against coronavirus
By ILANIT CHERNICK
In what could be a game-changer in the fight against Covid-19, Enovid, a coronavirus-killing nasal spray has officially gone on sale at pharmacies in Israel.
The Nitric Oxide Nasal Spray (NONS), developed by SaNOtize, which was co-founded by an Israeli scientist and is based in Canada, is designed to kill the virus in the upper airways, preventing it from incubating, spreading to the lungs and causing the illness.
Scientists believe that coronavirus is transmitted via airborne droplets to the mucous membranes in the nose, where it is replicated during a three-day incubation period, damaging the nasal mucosa cells, and is then carried in nasal secretions to the lower respiratory tract, leading to the danger of fatal viral pneumonia.
Last year, SaNOtize CEO and Israeli native Dr Gilly Regev announced during a special summit on coronavirus, which was hosted by Israel’s OurCrowd, that the company was pursuing clinical trials for the corona-killing nasal spray in the UK.
The UK trials began earlier this year with much success and followed independent lab tests at Utah State University’s Antiviral Research Institute, which proved that their treatment is 99.9% effective in killing coronavirus within two minutes.
As part of their research, studies done in rodents with COVID-19 infection showed over 95% reduction within the first day after infection. It is currently undergoing Phase II clinical trials throughout Canada approved by Health Canada and in other countries.
In the UK trials, Covid “patients with a self-administered nasal spray application found to have reduced SARS-CoV-2 log viral load by more than 95% in infected participants within 24 hours of treatment, and by more than 99% in 72 hours.”
According to Regev, SaNOtize’s technology is based on nitric oxide and supported by Nobel Prize-winning research, and “will be the only recognized therapy on the market proven to prevent COVID-19 from infecting the upper respiratory system.”
Earlier this year, Enovid “was granted an emergency use authorization as a medical device by Israel’s Ministry of Health.”
“Enovid releases a small dose of nitric oxide (NO), a natural nanomolecule with proven anti-microbial properties including against SARS-CoV-2, the virus that causes Covid-19,” the company explained in a statement.
Commenting on this momentous milestone, Dr Chris Miller, chief science officer and co-founder of SaNOtize said the company is “thrilled to have Enovid available in pharmacies in Israel.”
“We are moving as quickly and diligently as possible through regulatory approval
processes elsewhere in the world to make NONS available to the wider public,”
Concluding, Miller stressed that NONS have been shown to reduce viral load, “which decreases a person’s viral transmission, regardless of variant.”
The company has also made it clear that the nasal spray isn’t just useable against coronavirus – it’s also able to kill many other viruses in the upper respiratory system and nasal passages that could cause illnesses.
OurCrowd is an investor in SaNOtize.
**Featured Image Credit: Shutterstock